Podcasts about amag pharmaceuticals

Dr. Jennifer Gudeman, Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals discusses new clinical data from the pivotal phase 3 REST-ON clinical trial that was presented at the SLEEP 2021 Annual Meeting. The investigational therapy, FT218, for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy is currently under review at the FDA with a PDUFA target date of October 15, 2021. She also talks about the current treatment landscape and the unmet need among patients for a differentiated treatment option. #AvadelPharmaceuticals #SLEEP2021 Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs in December 2020. In 2017, Dr. Gudeman received the Healthcare Businesswomen's “Rising Star” award. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Dr Gudeman has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development in high-risk pregnancies. Prior to joining Avadel, Dr. Gudeman was Vice President, Medical Affairs at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Prior to her time at AMAG Pharmaceuticals, she was Director of Medical Affairs at Lumara Health. Additionally, she began her industry career at Mallinckrodt Pharmaceuticals. Dr. Gudeman graduated summa cum laude with a bachelor's degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy in 1999 and 2000, respectively.

Dr. Jennifer Gudeman is the Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals. In this episode, Dr. Gudeman and Claire discuss how Avadel Pharmaceuticals is seeking FDA approval for a once-nightly form of sodium oxybate (FT218) for the treatment of EDS and cataplexy in people with narcolepsy.  Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs at Avadel in December 2020. Avadel is a global biopharmaceutical company committed to improving the standard of care for people with narcolepsy. Dr. Gudeman and her team are focused on publications of primary and secondary data from the phase 3 REST-ON trial of investigational once-nightly FT218 and building out the medical affairs programs. They are also leading an ongoing open-label extension clinical study, called Restore, to evaluate the long-term safety and tolerability of investigational once-nightly FT218. Dr. Gudeman has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development. In 2017, Dr. Gudeman received the Healthcare Businesswomen’s “Rising Star” award. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Prior to joining Avadel, Dr. Gudeman was Vice President, Medical Affairs at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Dr. Gudeman graduated summa cum laude with a bachelor’s degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy in 1999 and 2000, respectively. To find out more information about Avadel’s Restore Study please go here. You can follow Wake Up Narcolepsy at @narcolepsy_360 on Instagram, @wakeupnarcolepsy on Instagram and Facebook and @wakenarcolepsy on Twitter. Let us know your thoughts about this episode by using the hashtag #narcolepsy360 and please rate and review us on Apple Podcasts.

This week we welcome as our guest Geoff Crouse the CEO of  Syneron Candela and a member of the Board of Directors. Geoff has successfully led businesses in the life sciences sector spanning capital equipment, diagnostics, and tools. Prior to joining Syneron Candela, he served as Chief Executive Officer of Cord Blood Registry from 2012 to 2015, when the company was sold to AMAG Pharmaceuticals. Prior, he served as Chief Operating Officer of Immucor, a publicly-traded company in the in-vitro diagnostics marketplace, and led Health Economics and Reimbursement Outcomes for Roche Diagnostics.

There are so many opportunities that come with having a nursing qualification. You are not only confined to bedside or outpatient nursing. You can use your qualification to work in research, administration, or pharmaceuticals, like today’s guest, Kevin Knoblock. As a nurse practitioner at Massachusetts General Hospital and a clinical scientist at AMAG Pharmaceuticals, Kevin has had a diverse professional journey. In today’s episode, we hear about the wide-ranging path Kevin has walked and how a range of qualifications has led to improvements in all his professional roles. We talk about some obstacles he faces in administration, where he stresses the importance of working in an integrated – rather than siloed – way. Kevin emphasizes the importance of staying at the top of your game if you work in healthcare. It is not the kind of career where you leave your work at work; it’s a lifestyle. Having been on both the management and clinical sides of healthcare, Kevin has excellent insights on communicating with those in administration. After sharing them, we also touch on the best advice he has received, his work with the non-profit, Human Rights Campaign, and why you should never underestimate the power of kindness. Tune in to hear more! Key Points From This Episode: • Why Kevin would choose flying as his superpower if he could.• Kevin’s diverse academic and professional background and the roles he has had.• Advice for those who are considering following the same path as Kevin.• Hear about Kevin’s journey as a nurse practitioner and what the role entails.• What gastroenterology involves.• How Kevin came to work in his role as a clinical scientist at AMAG Pharmaceuticals.• The biggest challenges Kevin faces in his administrative role.• Top tips on dealing with the administrative burden that many in clinical practice dread.• How Kevin stays on top of his learning in the fast-moving healthcare world.• Navigating communication with management and Kevin’s advice on how to approach it.• One of the standout moments from Kevin’s career as a nurse practitioner.• How having Crohn’s disease has helped Kevin be a better listener.• What Kevin would do to change healthcare in America if he could.• The best advice Kevin has been given and his favorite compliment he has received.• Kevin’s involvement with the Human Rights Campaign and what the organization does.• What's in store for nurse practitioners in the future.• Final words from Kevin: Always be positive and kind! Links Mentioned in Today’s Episode:Kevin Knoblock on LinkedInMassachusetts General HospitalAMAG PharmaceuticalsHuman Rights CampaignMGH Institute of Health ProfessionsUniversity of Minnesota, Carlson School of ManagementHarvard University, Extension SchoolBoston UniversityHuman Rights Campaign

Sonali Pandhe, PhD, Hematology-Oncology Medical Science Liaison at AMAG Pharmaceuticals, is "coming" to Syracuse on October 15th, 5-6 PM via Zoom. In the podcast, Sonali gives a sense of "a day in the life" of an MSL and offers a sneak peak at what you can expect in her Zoom webinar later this week. Be sure to tune in, and I hope you'll join us for her webinar!

In this episode, I talked with Mary Trout, Chief Commercial Officer at Candela, the medical laser company. We talked about building and supporting teams with execution focus and getting things done.   Mentioned in this episode: ·        https://candelamedical.com/na (Candela) ·        https://www.amagpharma.com/ (AMAG Pharmaceuticals) ·        https://www.cordblood.com/ (Cord Blood Registry) ·        https://en.wikipedia.org/wiki/Chiron_Corporation (Chiron Corporation) ·        http://suzanneledin.org/ (Suzanne Ledin) ·        https://www.bloomberg.com/profile/person/16473233 (Geoffrey Crouse)   ---   You can purchase your copy of The Art of Being Indispensable at Work from: ·        https://www.amazon.com/Art-Being-Indispensable-Work-Overcommitment/dp/1633698491/ (Amazon) ·        https://www.barnesandnoble.com/w/the-art-of-being-indispensable-at-work-bruce-tulgan/1135022362?ean=9781633698499 (Barnes & Noble) ·        https://www.indiebound.org/book/9781633698499 (Indiebound)   For bulk orders, contact us at: mail@rainmakerthinking.com   Follow Bruce on social media: ·        https://twitter.com/BruceTulgan (Twitter) ·        https://www.linkedin.com/in/brucetulganrmt/ (LinkedIn) ·        https://www.facebook.com/bruce.tulganRMT/ (Facebook)   Learn more about RainmakerThinking at our website: https://rainmakerthinking.com/ (rainmakerthinking.com)

Dr Jeffrey Chodakewitz, former EVP, Clinical Medicine and External Innovation, CMO at Vertex Pharmaceuticals, joins the Chief Medical Officer Summit for the first time to discuss his incredible journey as a CMO. Recorded at the 7th annual Chief Medical Officer Summit, Dr Chodakewitz sits down with Dr Julie Krop, AMAG Pharmaceuticals to discuss the following: The journeyPrioritizing resourcesSuccesses and failuresOvercoming hurdlesCareer decisionsTransitioning from large pharma to small biotechConsiderations for building your team in large and small companies Learn more at theconferenceforum.org

In an increasingly competitive market, there is a growing need for efficiency in attracting and retaining top talent. This session, recorded at the 7th annual Chief Medical Officer Summit, and moderated by Dr Julie Krop, AMAG Pharmaceuticals, addresses the following: How to source talent; pros and cons of recruiters versus word-of-mouthHow to make the work environment optimal to keep employees satisfiedHow to compete with the competition banging on the doorHow to ease or address relocation concerns of potential hiresWhen is a good time to have consultants or contractors filling the gapsHow to access the untapped talent in academia, do they know we exist?Benefit/risk of having non-MDs fill the gaps and guided by a physicianDoes the industry need to evolve to attract and retain talentHow do you decide whom to recruit firstHow to identify the right hire Panelists include: Kara Coluccio Bern, Perspective GroupJames Lewis, Barrington JamesChris Poshka, Govig Learn more at theconferenceforum.org

Dr. Alyssa Dweck discusses this condition that many women are uncomfortable talking to their healthcare providers about. Hypoactive sexual desire disorder or HSDD is biological and not a result of issues or unhappiness. It can be handled with the proper care and treatment. Learn more at www.Vyleesi.com. PRODUCT IS ONLY APPROVED FOR USE IN THE U.S. Sponsor: Interview courtesy of AMAG Pharmaceuticals.

When Ted Myles is asked to reflect back on his early efforts to land a CFO role – he arguably sounds a little bit like a safe cracker: “Breaking into the c-suite that first time is always hard,” he explains. “I went in and would continue to get beat out by a sitting CFO,” says Myles, who comments: “Understandably – a board or a CEO is always going to look for someone who’s already proven in the seat.” Having to date successfully decoded the c-suite’s entry formula not once but four times – the CFO seat at AMAG Pharmaceuticals is today filled by a seasoned CFO, who is routinely raising the bar for himself as well as AMAG’s finance team. This past January – six days into the new year – AMAG preannounced its 2019 earnings at the annual J.P. Morgan Healthcare Conference in San Francisco – an energetic gathering where the bio pharmaceutical crowd traditionally kicks off the new year with some blatant chest beating. “Our accounting team had about six total calendar days to provide us with a tight fix on what the accounting numbers were,” recalls Myles. “Fast forward six weeks after we got through an audit and the numbers were pretty much exactly what we announced six weeks earlier, ” explains AMAG’s finance leader, while exhibiting a little extra pride in the biotech firm’s fast and accurate close capabilities. At AMAG, apparently, the ease with which numbers are accessed is as worthy of note as the numbers themselves. – Jack Sweeney  NOW SUBSCRIBE: The Quarterly Digest of CFO Strategic Insight http://bit.ly/2Wfv291 (50 CFO Profiles Every Issue).

Shannon Gath, Head of Technology at AMAG Pharmaceuticals, joins host Maryfran Johnson to talk about gender diversity in IT, her approach to digital transformation, and the role of technology in telemedicine.

This podcasts gives you an overview on what to expect for the 2018 Chief Medical Officer Summit in a nutshell. The concept of the CMO Summit came from MPM Capital’s Dr Elizabeth Stoner, who told us that there is a deep need for a Summit that is designed for CMOs and heads of R&D in the emerging biotech space, specifically, where we can cover all the key issues affecting R&D decisions together with business development issues. The program takes place on May 7th and 8th at the Omni Parker House in Boston and we already have over 50 CMOs committed to attending. The program is co-chaired by Julie Krop, MD, CMO, EVP, Clinical Development & Regulatory Affairs, AMAG Pharmaceuticals, Inc,  and Jim Roach, MD, FACP, FCCP, CMO, Pulmatrix. The 6th Annual Chief Medical Officer Summit is produced by the Conference Forum. The Conference Forum is life science industry research firm that carefully and meticulously presents strategic level programming. As with all Conference Forum events, you can expect prominent networking. To learn more about the event, visit www.theconferenceforum.org. Be sure to use code TEML for a 10% discount. Thanks for listening.

Today in FirstWord:

Options Oddities 55: ZIOP, AMAG, FNFG Unusual Activity for October 27, 2014: Call buyers in Ziopharm Oncology Inc. (ZIOP) Call buyers in AMAG Pharmaceuticals, Inc. (AMAG) Put buyers in First Niagara Financial Group Inc. (FNFG)

Today in FirstWord:

Today in FirstWord: